We list below a summary of our corporate relationships - some details remain confidential.
NOVARTIS – Novartis has exclusive rights to develop and commercialize CMV alphavaccines under a December 2008 license agreement. This license was subsequently modified to cover other un-named indications.
DUKE UNIVERSITY – AlphaVax is a co-investigator with Duke on two cancer vaccine development grants from the National Cancer Institute and the Department of Defense, Breast Cancer Research Program.
MEMORIAL SLOAN-KETTERING CANCER CENTER – Following upon a number of pre-clinical studies for an immunotherapeutic against melanoma, a Phase I/II clinical study is under discussion.
NATIONAL INSTITUTES OF HEALTH (NIH) – AlphaVax has received eight grants from the NIH National Institute of Allergy and Infectious Disease (NIAID) for vaccine development against HIV and biodefense targets.
UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES (USAMRIID) – Alphavax has been a co-investigator with USAMRIID on four biodefense grants from the NIH.
CBMS-JOINT VACCINE ACQUISITION PROGRAM / DEPT. OF DEFENSE - AlphaVax has granted CBMS-JVAP an exclusive license to its alphavaccine platform for the development of Marburg and Ebola virus vaccines, and a license in a further indication.
HARRIS VACCINES/ MERCK ANIMAL HEALTH - AlphaVax has granted Harrisvaccines a license to develop vaccines for certain veterinary disease applications.